Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2023 filed with the SEC

September 1, 2023September 1, 2023 Alterity Therapeutics

XBRL 30 June 2023 filed with the SEC

Post navigation

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Related Posts

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

October 30, 2023October 30, 2023

Alterity Therapeutics Investor Presentation

April 10, 2019August 16, 2022

Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology

July 18, 2017August 16, 2022

Recent Posts

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065